The observational period will be 1 year (52 weeks) from the first brolucizumab administration in the primary treated eye.~However, if brolucizumab is discontinued in the primary treated eye and if the treatment is discontinued less than 52 weeks observation period, the observation period will be up to 90 days after the last dose of this drug. This is set in order to collect data as much as possible based on the clinical effect of the drug. If 30 days after the last dose of this drug in a discontinued patient exceeds 52 weeks of the observation period, the patient should be monitored for adverse events until 30 days after the last dose of this drug
This study is a prospective, uncontrolled, central registration system, multicenter, domestic observational study (special drug-use surveillance) to evaluate the safety of 52-week clinical treatment with Beovu kit for intravitreal injection in nAMD patients.